Trending

FibroGen

AstraZeneca shows cardiovascular safety for roxadustat

AstraZeneca shows cardiovascular safety for roxadustat

AstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm

X

AstraZeneca shows cardiovascular safety for roxadustat

https://pharmaphorum.com/news/astrazeneca-shows-cardiovascular-safety-for-roxadustat/

Galapagos and FibroGen drugs offer hope in IPF

Galapagos and FibroGen drugs offer hope in IPF

Drugs improve on existing medicines from Boehringer and Roche.

X

Galapagos and FibroGen drugs offer hope in IPF

https://pharmaphorum.com/news/galapagos-fibrogen-ipf/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com